Medivir AB
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 4 name spellings.
13
Ending by 2030
Mar 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 11, 2026The maintenance fee for SMAC mimetic (US 10,314,881) comes due Dec 11, 2026. Unpaid by Jun 11, 2027, it lapses early.
- 1 fee due Jan 2, 2027The maintenance fee for Dioxolane analogues of uridine for the treatment of cancer (US 10,336,780) comes due Jan 2, 2027. Unpaid by Jul 2, 2027, it lapses early.
- 1 fee due Jun 1, 2027The maintenance fee for Protease inhibitors (US 9,200,006) comes due Jun 1, 2027. Unpaid by Dec 1, 2027, it lapses early.
- 1 fee due Aug 9, 2027The maintenance fee for Pharmaceutical formulation for histone deacetylase inhibitors (US 9,255,066) comes due Aug 9, 2027. Unpaid by Feb 9, 2028, it lapses early.
- 1 fee due Sep 24, 2027The maintenance fee for SMAC mimetic (US 10,596,220) comes due Sep 24, 2027. Unpaid by Mar 24, 2028, it lapses early.
- 1 fee due Oct 9, 2027The maintenance fee for SMAC mimetic (US 11,951,147) comes due Oct 9, 2027. Unpaid by Apr 10, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 17, 2026
- 1 term has ended since Aug 17, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,517,906 | Dimeric Iap Inhibitors In force · High confidence | In force | High confidence | |
| US 7,671,032 | HCV NS-3 serine protease inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 8,242,119 | Protease inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 8,426,421 | Protease inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 9,200,006 | Protease inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 9,428,517 | Protease inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 8,933,052 | Uracyl Spirooxetane Nucleosides In force · Medium confidence | In force | Medium confidence | |
| US 8,283,372 | 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic In force · From the USPTO record | In force | From the USPTO record | |
| US 8,986,993 | SMAC Mimetic FOR TREATING MYELODYSPLASTIC SYNDROMES In force · Low confidence | In force | Low confidence | |
| US 10,034,912 | SMAC Mimetic In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 30: 2 patents in force now held by others · 79 lapsed for an unpaid fee · 38 ended at full term · 1 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 1 abandoned · 30 no status recorded